De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor

Medicina (Kaunas). 2021 Dec 27;58(1):37. doi: 10.3390/medicina58010037.

Abstract

Coronavirus disease 2019 has developed as a pandemic. Immunization with the introduction of vaccines against COVID-19 seems be the only way to end this pandemic. We report on a case of a kidney donor, who developed minimal change disease (MCD) within 4 days post-vaccination with the SARS-CoV-2 BNT162b2 mRNA vaccine (Pfizer/BioNTech). She donated her kidney to her husband 4 years ago. After receiving the 1st vaccine dose, she presented with nephrotic syndrome, with complete remission 5 days later. She proceeded with the second dose of the BNT162b2 vaccine at the appointed time. Two days later, she presented with a relapse of full-blown nephrotic syndrome with preserved renal function. We performed an ultrasound-guided percutaneous kidney biopsy and the final diagnosis was consistent with minimal change disease. Oral prednisolone was promptly initiated at a dosage of 1 mg/kg daily and complete remission was achieved 10 days later. More data about this rare appearance of de novo glomerular diseases after SARS-CoV-2 vaccination are emerging and should be interpreted rigorously.

Keywords: COVID-19 vaccination; SARS-CoV-2 mRNA vaccines; de novo glomerulonephritis; kidney donor; minimal change disease.

Publication types

  • Case Reports

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Female
  • Humans
  • Kidney Transplantation*
  • Nephrosis, Lipoid*
  • SARS-CoV-2
  • Vaccination
  • Vaccines, Synthetic
  • Viral Vaccines*
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • Vaccines, Synthetic
  • Viral Vaccines
  • mRNA Vaccines
  • BNT162 Vaccine